Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting -$2.8 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$2.8 million, down 324.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.6 million (down 120.09% YoY), and the FY2025 annual result was -$2.5 million, up 59.01% from the prior year.
• Net Income towards Common Stockholders came in at -$2.8 million for Q1 2026 at Cumberland Pharmaceuticals, down from -$1.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.2 million in Q1 2025 to a low of -$6.3 million in Q4 2023.
• The 4-year median for Net Income towards Common Stockholders is -$1.1 million (2024), against an average of -$1.4 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 1204.25% in 2024 and soared 165.61% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Net Income towards Common Stockholders stood at -$6.3 million in 2023, then surged by 74.7% to -$1.6 million in 2024, then surged by 32.31% to -$1.1 million in 2025, then tumbled by 160.17% to -$2.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.8 million (Q1 2026), -$1.1 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.